TriSalus publishes thyroid embolization study results

TriSalus Life Sciences Inc. (NASDAQ: TLSI) announced the publication of clinical data on its pressure-enabled drug delivery technology for thyroid treatment in the Journal of the Endocrine Society.

The retrospective single-center study evaluated the safety and efficacy of Pressure-Enabled Thyroid Artery Embolization using the TriNav Infusion System in 22 patients with symptomatic thyroid disease, including benign thyroid nodules or multinodular goiters. The median patient age was 59 years.

The study reported 100% technical and clinical success rates, with technical success defined as successful catheterization and embolization. Among seven patients with hyperthyroidism, 71% achieved normal thyroid function. The procedure resulted in a 73% mean reduction in thyroid gland volume at six months among 18 patients.

No major complications or neurovascular events occurred during the procedures. Mild post-procedure symptoms, such as neck discomfort, were reported in 81% of patients but resolved within two weeks. No patients developed hypothyroidism following the procedure.

The treatment involved pressure-enabled embolization via the inferior thyroid artery, with 45% of patients receiving unilateral treatment and 55% receiving bilateral treatment.

A multi-institutional registry study called PROTECT has been initiated in collaboration with TriSalus to validate these findings in a multi-center setting. The study is led by Juan C. Camacho, an interventional radiologist at Sarasota Memorial Hospital.

The authors concluded that pressure-enabled thyroid artery embolization represents a safe and feasible treatment option for large goiters and may provide an alternative to more invasive approaches for treating large benign thyroid nodules and benign multinodular goiters, though prospective research is needed to establish long-term efficacy.

You May Also Be Interested In